Showing of strength of AstraZeneca’s Airsupra in asthma

AstraZeneca’s (LSE: AZN) Airsupra (albuterol/budesonide) has met the primary endpoint of a Phase III trial, showing a statistically-significant and clinically-meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.

The BATURA trial included patients with intermittent or mild persistent asthma, including those on short-acting beta2-agonist (SABA) alone, low-dose inhaled corticosteroid (ICS) maintenance therapy, or leukotriene receptor antagonist (LTRA) maintenance therapy.

Airsupra, formerly known as PT027, is a first-in-class SABA/ICS rescue treatment for asthma in the USA, to be taken as needed.